Dec 11 (Reuters) – The U.S. Food and Drug Administration said on Thursday it has expanded the use of GSK’s Blujepa as an oral treatment for gonorrhea, a common sexually ‍transmitted infection.

The health regulator approved the drug, chemically known as gepotidacin, as an oral option for the treatment of uncomplicated urogenital gonorrhea in patients 12 years of age and older who have limited or no alternative treatment options.

Gonorrhea is caused by a bacteria called neisseria gonorrhoeae that ‌affects both men and women. If left untreated ‌or inadequately treated, it can lead to infertility and other sexual and reproductive health complications.

There were more than 600,000 cases of gonorrhea reported in the United States in 2023 according to the US Centers for Disease Control and Pre

See Full Page